Huadong Medicine's HDM1005 Receives FDA Approval for MASH Clinical Study
CompanyDrug

Huadong Medicine’s HDM1005 Receives FDA Approval for MASH Clinical Study

TenNor Therapeutics' Rifasutenizol Shows High Eradication Rate in H. pylori Phase III Study
CompanyDrug

TenNor Therapeutics’ Rifasutenizol Shows High Eradication Rate in H. pylori Phase III Study

Beijing Wantai Receives NMPA Clearance for Nine-Valent HPV Vaccine Targeting Male Population
CompanyDrug

Beijing Wantai Receives NMPA Clearance for Nine-Valent HPV Vaccine Targeting Male Population

Hasten Biopharmaceutical Initiates Phase III Clinical Trial for Lerodalcibep in China
CompanyDrug

Hasten Biopharmaceutical Initiates Phase III Clinical Trial for Lerodalcibep in China

VelaVigo and Avenzo Therapeutics Ink Global Partnership for Nectin4/TROP2 Bispecific ADC
CompanyDeals

VelaVigo and Avenzo Therapeutics Ink Global Partnership for Nectin4/TROP2 Bispecific ADC

Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments
CompanyDeals

Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments

Grand Pharmaceutical Group Expands Distribution Partnership with Sirtex Medical in China
CompanyDeals

Grand Pharmaceutical Group Expands Distribution Partnership with Sirtex Medical in China

Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336
CompanyDeals

Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336

CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine
CompanyDrug

CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine

Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments
CompanyDeals

Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments

NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology
CompanyDeals

NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology

Shanghai's Matwings Secures Over $13.8 Million in Series A Financing for AI Protein Design
CompanyDeals

Shanghai’s Matwings Secures Over $13.8 Million in Series A Financing for AI Protein Design